Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands.
Department for Health Evidence, Radboud university medical center (Radboudumc), Nijmegen, Netherlands.
Nat Rev Clin Oncol. 2023 May;20(5):287-304. doi: 10.1038/s41571-023-00744-3. Epub 2023 Mar 13.
Bladder cancer is among the ten most common cancers globally, causes considerable morbidity and mortality and is, therefore, a substantial burden for health-care systems. The incidence of bladder cancer is affected by demographic trends, most notably population growth and ageing, as well as exposure to risk factors, especially tobacco smoking. Consequently, the incidence has not been stable throughout the world over time, nor will it be in the near future. Further primary prevention efforts are of the utmost importance to reduce the medical and financial burden of bladder cancer on populations and health-care systems. Simultaneously, less-invasive and lower-cost approaches for the diagnosis of both primary and recurrent bladder cancers are required to address challenges posed by the increasing shortage of health-care professionals and limited financial resources worldwide. In this regard, urinary biomarkers have demonstrated promising diagnostic accuracy and efficiency. Awareness of the risk factors and symptoms of bladder cancer should also be increased in society, particularly among health-care professionals and high-risk groups. Studies investigating the associations between lifestyle factors and bladder cancer outcomes are scarce and should be a research priority. In this Review, we outline global trends in bladder cancer incidence and mortality, and discuss the main risk factors influencing bladder cancer occurrence and outcomes. We then discuss the implications, challenges and opportunities of these epidemiological trends for public health and clinical practice.
膀胱癌是全球十大常见癌症之一,导致相当高的发病率和死亡率,因此对医疗保健系统构成了重大负担。膀胱癌的发病率受到人口趋势的影响,特别是人口增长和老龄化,以及接触危险因素,特别是吸烟。因此,膀胱癌的发病率在全球范围内并非一直保持稳定,在不久的将来也不会稳定。进一步开展初级预防工作对于减轻膀胱癌对人群和医疗保健系统的医疗和经济负担至关重要。同时,需要采用创伤更小、成本更低的方法来诊断原发性和复发性膀胱癌,以应对全球医疗保健专业人员短缺和有限的财政资源带来的挑战。在这方面,尿液生物标志物已显示出有希望的诊断准确性和效率。社会,特别是医疗保健专业人员和高危人群,也应该提高对膀胱癌风险因素和症状的认识。研究生活方式因素与膀胱癌结果之间的关联的研究很少,应该成为研究的重点。在这篇综述中,我们概述了膀胱癌发病率和死亡率的全球趋势,并讨论了影响膀胱癌发生和结果的主要危险因素。然后,我们讨论了这些流行病学趋势对公共卫生和临床实践的影响、挑战和机遇。
Nat Rev Clin Oncol. 2023-5
Eur Urol. 2016-10-28
2017-11-3
Eur Urol Oncol. 2022-12
Scand J Urol Nephrol Suppl. 2008-9
EJNMMI Radiopharm Chem. 2025-8-30
JCO Clin Cancer Inform. 2025-8
Front Urol. 2024-5-20
Abdom Radiol (NY). 2025-7-28
Transl Androl Urol. 2025-6-30
Bladder Cancer. 2022-9-15
Immunol Invest. 2022-11
Chem Res Toxicol. 2022-10-17